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REGULATORY QUESTION: STARTING MATERIALS?
A.Small molecule drugs
(i) sufficient propinquity (excluding purifications)
(ii) essential structural element of API
(iii) structurally not too complex
(iv) well defined and stable (isolated) chemical
(v) well defined impurity profile (incl. related impurities, residual solvents, metals and others)
(vi) preferably widely commercially available, but custom synthesis allowed Sta
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Analytical methods
Oligo/Poly peptides/nucleotides
• Propinquity not valid
Specifications   control strategy
Semi-synthetic molecules
• Source material: micro-organisms (fermentation) or plant material (extraction)
cave:
impurity profile of drug substance influenced by fermentation or extraction?
risk assessment: microbial or other contamination?
• Isolated intermediates (compliant with general SM definition)
B. Biological drugs
QbD
DEFINING STARTING MATERIALS
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Biological drugs of non-recombinant origin
• substance of biological origin: 
micro organisms, organs, tissues of plant or animal origin
cells or fluid (incl. blood, plasma or urine) of human or animal origin
Biological drugs of recombinant origin
• biotechnological cell constructs (master/working cell bank)
Immunologicals
• biotechnological cell constructs (master/working cell bank)
Plasma derived drugs
• Plasma of human or animal origin. cave: collection/procurement/testing
Advanced Therapeutic Medicinal Products (ATMP)
(somatic) Cell / Tissue therapy
• harvested cells/tissues. cave: donation/procurement/testing
• additional substances (scaffolds, matrices, devices, biomaterials) which are combined with the 
manipulated cells
Gene therapy
• master virus vector seed
• plasmid
• master cell bank of packaging cell line / host bacteria
